$30M VXM01 IP Acquisition Centralizes Key Drug Ownership for OSR Holdings
Summary
OSR Holdings has acquired the full global intellectual property portfolio for its VXM01 cancer immunotherapy from VAXIMM AG for $30 million. This transaction, which is significantly larger than OSRH's current market cap, centralizes ownership of the Phase 3-ready asset at the parent level. It follows the definitive global exclusive license agreement for VXM01 with BCM Europe AG announced in late April, and an earlier 8-K/A that disclosed an option for full acquisition. The acquisition is expected to enhance licensing flexibility and long-term royalty economics for OSRH shareholders. The $30 million purchase price becomes payable upon the first milestone event under the BCME License Agreement, specifically the completion of a Phase 2 clinical study for VXM01.
At the time of this announcement, OSRH was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.38 to $1.79. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: ACCESS Newswire.